retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity π¨ Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. π Mean body weight change at 80 weeks: β¬οΈ Retatrutide vs Tirzepatide Compared |
Pay in 4 interest-free payments of $5.76 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 1 - Aug 6


00967-0/asset/1cda1e69-507e-47d1-ad73-620bcd1cbb66/main.assets/gr2_lrg.jpg)

























